Investment Update
Natco Pharma Ltd announced on Monday that it will increase its planned outlay for U.S. biotechnology company eGenesis Inc to **USD 16.70 million** (about **₹139 crore**). The revised figure supersedes the earlier disclosed amount of USD 14 million.
Structure of the Deal
Under the new arrangement, **NATCO Pharma (Canada) Inc** will contribute **USD 13.70 million**, while **NATCO Pharma USA LLC** will add **USD 3 million**. The transaction will be settled in cash and involves the purchase of **convertible promissory notes** that carry an **8 % compounded annual interest rate**. No shares are being acquired at the time of completion, which is expected by **31 October**.
Strategic Rationale
Natco had already invested **USD 8 million** in eGenesis earlier in 2024 through its Canadian subsidiary. With the new investment, the Indian drugmaker’s total stake in the U.S. firm will reach **USD 24.70 million**. The company stated that the additional funding is intended to back eGenesis’s “new‑age therapeutic programmes addressing critical unmet medical needs.”
Future Outlook
The deal is a step toward deepening Natco’s presence in the global biotechnology arena. While the current transaction does not involve a share purchase, the convertible notes could provide an equity conversion option in the future, potentially expanding Natco’s influence in eGenesis’s development pipeline.
Why It Matters
For Natco, the move signals a continued commitment to high‑impact, research‑intensive ventures beyond its traditional therapeutic areas. For the U.S. biotech sector, the infusion of capital from an Indian firm underscores the growing cross‑border collaboration in drug development. The completion of the transaction by the end of October will mark a significant milestone in Natco’s international expansion strategy.